search
Back to results

Concentrating on Antisepsis: 5% vs. 10% Povidone-Iodine Prior to Intravitreal Injection

Primary Purpose

Endophthalmitis, Eye Infections

Status
Unknown status
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
Bacterial Culture Swab
Sponsored by
Matthew Bolton
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Endophthalmitis focused on measuring intravitreal injection, povidone-iodine, ocular surface flora, endophthalmitis, betadine

Eligibility Criteria

18 Years - 100 Years (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • enrollment will be open to men and women of all ethnic backgrounds between the ages of 18-100 who are offered intravitreal injections by Dr. Anthony Mazzulla at his Retina clinic at the Ochsner Clinic Foundation as a treatment for diabetic macular edema, proliferative diabetic retinopathy, age related exudative macular degeneration, or any other cause of choroidal neovascularization or cystoid macular edema.

Exclusion Criteria:

  • Current eye infection, actively treated blepharitis, current use of topical or systemic antimicrobial agents, current use of topical or systemic corticosteroids, allergy to iodine, pregnancy, children.

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm 3

    Arm Type

    Experimental

    Experimental

    Experimental

    Arm Label

    5% Betadine, Ocular Surface only

    10% Betadine, Ocular Surface only

    10% Betadine, Ocular Surface and Adnexa

    Arm Description

    Use of 5% P-I from bottle dropper to sterilize the ocular surface only, prior to injection. Intervention: bacterial culture swab.

    Use of 10% P-I swabstick to sterilize the ocular surface only, prior to injection. Intervention: bacterial culture swab.

    Use of 10% P-I swabstick to sterilize the ocular surface and surrounding lids and eyelashes only, prior to injection. Intervention: bacterial culture swab.

    Outcomes

    Primary Outcome Measures

    Median Colony-Forming Units
    Median CFUs compared pre- and post-injection

    Secondary Outcome Measures

    Patient's ocular surface symptoms during sterilization with povidone-iodine
    Survey-based

    Full Information

    First Posted
    January 16, 2018
    Last Updated
    January 28, 2018
    Sponsor
    Matthew Bolton
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT03420820
    Brief Title
    Concentrating on Antisepsis: 5% vs. 10% Povidone-Iodine Prior to Intravitreal Injection
    Official Title
    Concentrating on Antisepsis: 5% vs. 10% Povidone-Iodine Prior to Intravitreal Injection
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    January 2018
    Overall Recruitment Status
    Unknown status
    Study Start Date
    March 1, 2018 (Anticipated)
    Primary Completion Date
    April 1, 2018 (Anticipated)
    Study Completion Date
    July 1, 2018 (Anticipated)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Sponsor-Investigator
    Name of the Sponsor
    Matthew Bolton

    4. Oversight

    Studies a U.S. FDA-regulated Drug Product
    No
    Studies a U.S. FDA-regulated Device Product
    No
    Data Monitoring Committee
    No

    5. Study Description

    Brief Summary
    This is a randomized controlled single blind prospective study evaluating the efficacy of ocular surface sterilization between three different povidone-iodine preparation techniques prior to intravitreal injection. The primary end point is significant different between median colony-forming units pre- and post-sterilization and injection.
    Detailed Description
    Introduction: An estimated 5.9 - 7.9 million intravitreal injections (IVI) were given in 2016. While the incidence of post-injection endophthalmitis is exceedingly low, it is a feared complication of the procedure. 96% of culture-positive post-injection endophthalmitis cases are caused by conjunctival commensals, emphasizing the importance of ocular surface sterilization prior to IVI. The most recently published guidelines for IVI state that "Povidone-Iodine (5-10%) should be the last agent applied to the intended injection site before the injection," a recommendation that is universally followed. However, there is no standard of care regarding the concentration of PI nor the field of sterilization (e.g, cleaning the eyelids and lashes), and technique varies widely in clinical practice. The literature reveals no direct comparison of 5% vs 10% PI in the context of intravitreal injection. Methods: Single-center randomized prospective trial enrolling patients into three protocols: 5% P-I applied to ocular surface from bottle, 10% P-I swabstick applied to ocular surface, and 10% P-I swabstick applied to lids, lashes, and ocular surface. Pre-procedure cultures will be obtained from the ocular surface, and a second culture will be taken following antisepsis, injection, and irrigation. Standard microbiologic techniques will be used to collect, culture, identify, and quantify ocular surface bacteria counts. Kruskal Wallis test will be used to assess significant difference between median bacterial loads at baseline and post-cleaning, as well as median reduction from baseline. Chi-squared test will be used to assess significant difference between reduction in number of patients with specific bacteria. Following injection, a patient survey will be administered to compare patients' subjective symptoms of ocular surface irritation during the PI preparation phase of the procedure. Conclusions: The investigators anticipate that no significant difference exists in decrease of median CFUs between the three protocols, and that lower concentration of P-I provides a more comfortable patient experience.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Endophthalmitis, Eye Infections
    Keywords
    intravitreal injection, povidone-iodine, ocular surface flora, endophthalmitis, betadine

    7. Study Design

    Primary Purpose
    Prevention
    Study Phase
    Not Applicable
    Interventional Study Model
    Parallel Assignment
    Masking
    Participant
    Allocation
    Randomized
    Enrollment
    30 (Anticipated)

    8. Arms, Groups, and Interventions

    Arm Title
    5% Betadine, Ocular Surface only
    Arm Type
    Experimental
    Arm Description
    Use of 5% P-I from bottle dropper to sterilize the ocular surface only, prior to injection. Intervention: bacterial culture swab.
    Arm Title
    10% Betadine, Ocular Surface only
    Arm Type
    Experimental
    Arm Description
    Use of 10% P-I swabstick to sterilize the ocular surface only, prior to injection. Intervention: bacterial culture swab.
    Arm Title
    10% Betadine, Ocular Surface and Adnexa
    Arm Type
    Experimental
    Arm Description
    Use of 10% P-I swabstick to sterilize the ocular surface and surrounding lids and eyelashes only, prior to injection. Intervention: bacterial culture swab.
    Intervention Type
    Biological
    Intervention Name(s)
    Bacterial Culture Swab
    Intervention Description
    Culture swabs will be obtained before application of PI and after injection.
    Primary Outcome Measure Information:
    Title
    Median Colony-Forming Units
    Description
    Median CFUs compared pre- and post-injection
    Time Frame
    3 months
    Secondary Outcome Measure Information:
    Title
    Patient's ocular surface symptoms during sterilization with povidone-iodine
    Description
    Survey-based
    Time Frame
    3 months

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    18 Years
    Maximum Age & Unit of Time
    100 Years
    Accepts Healthy Volunteers
    Accepts Healthy Volunteers
    Eligibility Criteria
    Inclusion Criteria: enrollment will be open to men and women of all ethnic backgrounds between the ages of 18-100 who are offered intravitreal injections by Dr. Anthony Mazzulla at his Retina clinic at the Ochsner Clinic Foundation as a treatment for diabetic macular edema, proliferative diabetic retinopathy, age related exudative macular degeneration, or any other cause of choroidal neovascularization or cystoid macular edema. Exclusion Criteria: Current eye infection, actively treated blepharitis, current use of topical or systemic antimicrobial agents, current use of topical or systemic corticosteroids, allergy to iodine, pregnancy, children.
    Central Contact Person:
    First Name & Middle Initial & Last Name or Official Title & Degree
    Matthew Bolton, MD
    Phone
    504-495-5631
    Email
    mbolt3@lsuhsc.edu
    Overall Study Officials:
    First Name & Middle Initial & Last Name & Degree
    Donald Mazzulla, MD
    Organizational Affiliation
    Ochsner Health System
    Official's Role
    Principal Investigator

    12. IPD Sharing Statement

    Plan to Share IPD
    No

    Learn more about this trial

    Concentrating on Antisepsis: 5% vs. 10% Povidone-Iodine Prior to Intravitreal Injection

    We'll reach out to this number within 24 hrs